Dosage and Administration of anti-a Antibodies in combination with ErbB3 Tyrosine Kinase Inhibitors.

• 收藏
• 分享

专利权人:

SANOFI;MERRIMACK PHARMACEUTICALS, INC.; INC.;MERRIMACK PHARMACEUTICALS

发明人:

KUBASEK, WILLIAM,MOYO, VICTOR,ONSUM, MATTHEW DAVID,NERING, RACHEL,DHINDSA, NAVREET,MACBEATH, GAVIN,PEARLBERG, JOSEPH,TABAH-FISCH, ISABELLE

申请号：

UY34131

公开号：

UY34131A

申请日:

2012.06.15

申请国别(地区):

UY

年份:

2013

代理人:

摘要：

Methods and compositions are provided for the Clinical Treatment of NSCLC using anti ErbB3 Antibodies combined with the use of TKI, such as erlotinib or gefitinib.Se proporcionan métodos y composiciones para el tratamiento clínico de NSCLC usando anticuerpos anti-ErbB3 combinados con el uso de TKI tales como erlotinib o gefitinib.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/